SAN DIEGO, May 18 /PRNewswire/ -- NovaRx Corporation announced today that it has successfully achieved full enrollment over a year ahead of schedule in its multi-center Phase II clinical trial treating individuals with advanced stages of lung cancer. The Phase II study is designed to determine the safety and efficacy of a novel therapeutic concept under development by NovaRx. In contrast to conventional cancer therapies, where chemotherapeutic drugs destroy the tumor, the therapeutic vaccine developed by NovaRx enhances the patient's own immune system in order to fight the cancer. In clinical studies to date, the side effects of this treatment have been shown to be far less than those associated with traditional therapies.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020204/LAM044LOGO )
"The accelerated enrollment in this trial is extremely encouraging and is a strong indication of the fact that the clinical investigators are hopeful that NovaRx's therapeutic vaccine being tested may lead to an effective treatment of this deadly disease," said Dr. Habib Fakhrai, President and CEO of NovaRx.
The therapeutic vaccine being developed by NovaRx consists of non-small cell lung cancer cell lines that were originally derived from lung cancer patients. These cell lines are genetically modified through the introduction of a gene that blocks a molecule called transforming growth factor-beta (TGF-Beta). TGF-Beta is a potent agent commonly produced by cancer cells that paralyzes the immune system. The vaccine has been previously shown to induce therapeutic immune responses in cancer patients and it is believed that this will significantly extend survival by destroying, halting, or delaying progression of the disease.
NovaRx Corporation holds the exclusive worldwide license for this patented technology for the treatment and prevention of numerous indications, including but not limited to lung, brain and colon cancers.
NovaRx Corporation is a privately held biopharmaceutical company based in San Diego, California. The company is dedicated to developing new therapeutic approaches for treating cancer with its lead indication focused on non-small cell lung cancer, which is responsible for approximately 170,000 deaths in the U.S. each year and is the number one cause of cancer death throughout the world. Additionally, the company is planning to initiate a multi-center pivotal Phase II/III clinical trial treating individuals with brain cancer in 2005. Last week the company announced that it was the recipient of an additional National Institutes of Health grant totaling $2.2 million over a four year period. The proceeds from this grant will partially offset the cost of the pivotal Phase II/III brain cancer trial. Brain cancer affects over one million people worldwide.
For more information on the company, please visit their website at http://www.novarx-pharma.com/
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020204/LAM044LOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, email@example.comNovaRx Corporation